Zhanhong Chen
Overview
Explore the profile of Zhanhong Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shao X, Xie N, Chen Z, Wang X, Cao W, Zheng Y, et al.
J Transl Int Med
. 2024 Nov;
12(5):466-477.
PMID: 39513033
Objective: We aimed to investigate the pharmacokinetics, safety, efficacy, and immunogenicity of different dosing regimens (weekly and every three weeks) of inetetamab in combination with vinorelbine in human epidermal growth...
2.
Xu J, Fang W, Zhou H, Jiang R, Chen Z, Wang X
Biotechnol Bioeng
. 2024 Oct;
122(1):30-43.
PMID: 39402769
Due to its high heterogeneity and significant impact on women's health globally, breast cancer necessitates robust preclinical models to understand tumor biology and guide personalized treatment strategies. Three-dimensional (3D) in...
3.
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, et al.
EClinicalMedicine
. 2024 Oct;
76:102837.
PMID: 39380967
Background: The phase 2 PERMEATE study has shown the antitumor activity and safety of pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer...
4.
Xu C, Chen Z, Xia Y, Shi Y, Fu P, Chen Y, et al.
Cancer
. 2024 Aug;
130(S17):3054-3066.
PMID: 39092590
Antibody-drug conjugates (ADCs) have demonstrated effectiveness in treating various cancers, particularly exhibiting specificity in targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Recent advancements in phase 3 clinical...
5.
Wang X, Sharma K, Chen Z, Wang S
Asia Pac J Oncol Nurs
. 2024 Jun;
11(6):100491.
PMID: 38845749
No abstract available.
6.
Xu J, Chen J, Huang P, Zhou H, Wang X, Chen Z
Transl Breast Cancer Res
. 2024 May;
4:25.
PMID: 38751473
Background: We report a case of metastatic human epidermal growth factor receptor-2 (HER2) positive breast cancer who achieved encouraging clinical benefits across multiple pyrotinib-based anti-HER2 therapies. Case Description: A 33-year-old...
7.
Zheng Y, Cao W, Shao X, Shi Y, Cai L, Chen W, et al.
Nat Commun
. 2023 Dec;
14(1):8314.
PMID: 38097605
The role of pyrotinib in the treatment of HER2-positive metastatic breast cancer (MBC) has been well-established. This multicenter, single-arm phase II trial (NCT03876587) aimed to assess the benefit of pyrotinib...
8.
Liu F, Wei X, Chen Z, Chen Y, Hu P, Jin Y
J Cancer Res Clin Oncol
. 2023 Jun;
149(12):10737-10752.
PMID: 37311985
Purpose: This study was to investigate the biological effect of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) in colorectal cancer (CRC). Methods: PFKFB2 was selected by metabolism polymerase chain reaction (PCR) array from CRC...
9.
Fang T, Lu W, Zhang J, Ge K, Chen Z, Wang M, et al.
Anal Chem
. 2022 Nov;
94(48):16919-16926.
PMID: 36420757
Drug resistance in chemotherapy has been greatly challenging for cancer treatment. Research has revealed that extracellular vesicles (EVs) secreted by drug-resistant cells could induce chemoresistance in susceptible cells. However, there...
10.
Wang T, Wei L, Lu Q, Shao Y, You S, Yin J, et al.
NPJ Precis Oncol
. 2022 Nov;
6(1):84.
PMID: 36369474
Recurrent fusions of receptor tyrosine kinases (RTKs) are often driving events in tumorigenesis that carry important diagnostic value and are potentially targetable by the increasing number of tyrosine kinase inhibitors...